In this article, Doctors and their patients (in Rochester Minn.) with a specific type of breast cancer called ductal carcinoma in situ (DCIS) are successfully giving and discovering treatments to beat the disease, along with 10-year survival rates getting close to nearly 100 percent.
DCIS happens when lots of abnormal cells multiply and form a growth within a breast's milk duct. The cells are considered cancerous, but luckily have remained in place within the milk duct. "In situ" means "in place."
Annually in the United States more than 62,000 cases are diagnosed with DCIS, making it the most rapidly increasing type of noninvasive cancer. Meaning a type of cancer that remains in one place, and does not invade adjacent or nearby healthy cells, blood vessels, or tissues.
Researchers are attempting to better understand which women with DCIS are at highest and lowest risk of recurrence. They believe that that information would help in determining the most appropriate treatment. In the meantime, patients and their care providers or doctors
should discuss the pros and cons of all treatment approaches. DCIS isn't considered life threatening, but, if not detected and treated, it can progress to a more serious form of invasive cancer. The best treatment approach is still being debated.